"We are delighted to have received FDA Breakthrough Device Designation for AVIM therapy which has the potential to offer a differentiated, advantageous solution for hypertension management in a broad population," commented David Hochman, Chairman …

… ablation catheter for treatment of paroxysmal atrial fibrillation (PAF). … -arm, multi-center trial performed in European centers … technologies and therapies treat 70 health conditions … and management of atrial fibrillation developed in collaboration with …

… the groundbreaking LeAPPS Clinical Trial, an international study aimed … with risk factors for atrial fibrillation and ischemic stroke. This … participate in this essential trial to help reduce stroke … community access top-quality treatment close to home.” By …

… multi-center, non-randomized clinical trial that evaluates the safety and … pulsed field ablation (PFA) in atrial fibrillation treatment, particularly for pulmonary vein isolation … information or future events or developments. © Johnson & Johnson and its …

… atrial fibrillation symptoms and long episodes of atrial fibrillation (LEAF) FDA … drug.  Patent No. 12,115,373 instructs a physician treating … with anti-arrhythmic drugs (AAD), electrophysiological … company committed to developing innovative therapies for …

… treating ventricular arrhythmia, or irregular heart rhythm, including atrial fibrillation … physicians use the FDA-approved technology to … -invasive procedures to treat atrial and ventricular … develop novel leading-edge technologies to improve treatment …

A large-scale study published in Heart finds brisk walking at over four miles per hour lowers the risk of cardiac arrhythmias by 43 percent, offering an accessible and powerful strategy for heart health. By yourNEWS Media Newsroom A groundbreaking study …

… as adjunctive treatment for persistent atrial fibrillation (AF). The single-arm, prospective trial focused … cavotricuspid isthmus (CTI) ablation to treat typical atrial flutter (AFL). Subjects … is expected to receive the FDA approval for expanded use labelling …

… -controlled, double-blind trial commenced subject enrolment and … products, incidence of new atrial fibrillation cases, and the … potential to transform the treatment landscape of cardiac … complications.” Renibus Therapeutics develops products for preventing the …

… technologies aimed at improving treatment for transcatheter tricuspid … advancement in the treatment of tricuspid valve regurgitation … factors include heart disease, atrial fibrillation, pulmonary hypertension, and more … approval of the FDA for TriClip G4 and …